Quantcast

Latest Fludarabine Stories

2012-12-12 23:28:43

-People who develop chronic lymphocytic leukemia (CLL) are typically age 65 and older, but participants in CLL clinical trials are usually several years younger; -The age of CLL patients is not usually considered when determining treatment; -This study suggests that older and younger CLL patients require different therapy. Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the...

2012-12-10 15:13:30

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). CLL is a blood cancer that causes abnormal white blood cells called lymphocytes to accumulate in the blood, bone marrow, and in the lymph nodes or other organs,...

2012-05-17 11:04:24

-Standard treatment for chronic leukemia is too harsh for many older patients. -Early clinical trials testing indicates that these patients respond well to the experimental drug ibrutinib. -This agent merits further testing as a first-line therapy for older chronic-leukemia patients. The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of older patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase...

2011-11-02 08:42:28

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a study in the...

2011-06-17 00:30:00

SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab ("FPD-R") replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma ("INHL"). The Phase I-II...

2011-02-25 15:26:29

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients. The multi-institutional study, led by researchers at the Ohio State University Comprehensive Cancer Center...

2010-10-04 13:16:02

(Ivanhoe Newswire) -- The monoclonal antibody rituximab given in addition to a standard chemotherapy regimen, significantly prolongs the lives of patients with chronic lymphocytic leukemia, a new study shows. According to the Mayo Clinic, chronic lymphocytic leukemia or CLL is a type of cancer of the blood and bone marrow. The "lymphocytic" in CLL comes from the cells affected by the disease, a group of white blood cells called lymphocytes, which helps your body fight infection. About 15,000...

2010-10-04 06:00:00

PITTSBURGH, Oct. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a...

2010-07-01 17:05:00

WASHINGTON, July 1 /PRNewswire-USNewswire/ -- Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology. About 15,000 new CLL cases were diagnosed in the United States in 2009 and about 4,000 deaths were...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related